Venous thromboembolic events in hospitalised medical patients

 

 Buy Article Permissions and Reprints

Summary

The number of acutely ill hospitalised medical patients at risk for acute venous thromboembolism (VTE) has not been well defined. Therefore, we used the 2003 United States Healthcare Cost and Utilization Project (HCUP) Nationwide Inpatient Sample database to estimate VTE events among hospitalised medical patients. We then modeled the potential reduction in VTE with universal utilisation of appropriate pharmacological thromboprophylaxis. We calculated that 8,077,919 acutely ill hospitalised medical patients were at risk for VTE. Heart failure, respiratory failure, pneumonia, and cancer were the most common medical diagnoses. We estimated that 196,134 VTE-related events occurred in 2003, afflicting two out of every 100 acutely ill hospitalised medical patients. These VTE-related events were comprised of 122,235 symptomatic deep venous thromboses, 32,654 symptomatic episodes of pulmonary embolism, and 41,245 deaths due to VTE. In our model, rates of pharmacological thromboprophylaxis prescription were low for various acute medical illnesses, ranging from 15.3% to 49.2%. However, with universal thromboprophylaxis, 114,174 VTE-related events would have been prevented. In conclusion, acutely ill medical patients represent a large population vulnerable to the development of VTE during hospitalisation. The number of VTE-related events would be halved with universal thromboprophylaxis. Further efforts focused on improving VTE prevention strategies in hospitalised medical patients are warranted.

• References

• 1 MacDougall DA, Feliu AL, Boccuzzi SJ. et al. Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome. Am J Health Syst Pharm 2006; 63: S5-15.
  CrossrefPubMedGoogle Scholar
• 2 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149: 698-707.
  CrossrefPubMedGoogle Scholar
• 3 Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: an updated review. Curr Opin Cardiol 2008; 23: 555-559.
  CrossrefPubMedGoogle Scholar
• 4 Piazza G, Seddighzadeh A, Goldhaber SZ. Double trouble for 2,609 hospitalised medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 2007; 132: 554-561.
  CrossrefPubMedGoogle Scholar
• 5 Spencer FA, Lessard D, Emery C. et al. Venous thromboembolism in the outpatient setting. Arch Intern Med 2007; 167: 1471-1475.
  CrossrefPubMedGoogle Scholar
• 6 Geerts WH, Bergqvist D, Pineo GF. et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133: 381S-453S.
  CrossrefPubMedGoogle Scholar
• 7 Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
  PubMedGoogle Scholar
• 8 Amin A, Stemkowski S, Lin J. et al. Thromboprophylaxis rates in US medical centers: success or failure?. J Thromb Haemost 2007; 05: 1610-1616.
  CrossrefPubMedGoogle Scholar
• 9 Kahn SR, Panju A, Geerts W. et al. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res 2007; 119: 145-155.
  CrossrefPubMedGoogle Scholar
• 10 Cohen AT, Tapson VF, Bergmann JF. et al. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-394.
  CrossrefPubMedGoogle Scholar
• 11 Anderson Jr FA, Zayaruzny M, Heit JA. et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 2007; 82: 777-782.
  CrossrefPubMedGoogle Scholar
• 12 Cohen AT, Agnelli G, Anderson FA. et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Yu HT, Dylan ML, Lin J. et al. Hospitals’ compliance with prophylaxis guidelines for venous thromboembolism. Am J Health Syst Pharm 2007; 64: 69-76.
  CrossrefPubMedGoogle Scholar
• 14 Warlow C, Terry G, Kenmure AC. et al. A doubleblind trial of low doses of subcutaneous heparin in the prevention of deep-vein thrombosis after myocardial infarction. Lancet 1973; 02: 934-936.
  PubMedGoogle Scholar
• 15 Sherman DG, Albers GW, Bladin C. et al. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 2007; 369: 1347-1355.
  CrossrefPubMedGoogle Scholar
• 16 Khorana AA, Francis CW, Culakova E. et al. Thromboembolism in hospitalised neutropenic cancer patients. J Clin Oncol 2006; 24: 484-490.
  CrossrefPubMedGoogle Scholar
• 17 Harenberg J, Schomaker U, Flosbach CM. Enoxaparin is superior to unfractionated heparin in the prevention of thromboembolic events in medical patients at increased thromboembolic risk. Blood 1999; 94 Suppl 399a.
  PubMedGoogle Scholar
• 18 Handley AJ. Low-dose heparin after myocardial infarction. Lancet 1972; 02: 623-624.
  PubMedGoogle Scholar
• 19 Cohen AT, Turpie AG, Leizorovicz A. et al. Thromboprophylaxis with dalteparin in medical patients: which patients benefit?. Vasc Med 2007; 12: 123-127.
  CrossrefPubMedGoogle Scholar
• 20 Alikhan R, Cohen AT, Combe S. et al. Risk factors for venous thromboembolism in hospitalised patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004; 164: 963-968.
  CrossrefPubMedGoogle Scholar
• 21 Alikhan R, Cohen AT, Combe S. et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003; 14: 341-346.
  CrossrefPubMedGoogle Scholar
• 22 Oster G, Tuden RL, Colditz GA. A cost-effectiveness analysis of prophylaxis against deep-vein thrombosis in major orthopedic surgery. J Am Med Assoc 1987; 257: 203-208.
  CrossrefPubMedGoogle Scholar
• 23 Ades AE, Claxton K, Sculpher M. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis. Health Econ 2006; 15: 373-381.
  CrossrefPubMedGoogle Scholar
• 24 Doubilet P, Begg CB, Weinstein MC. et al. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 05: 157-177.
  CrossrefPubMedGoogle Scholar
• 25 Stein PD, Beemath A, Meyers FA. et al. Incidence of venous thromboembolism in patients hospitalised with cancer. Am J Med 2006; 119: 60-68.
  CrossrefPubMedGoogle Scholar
• 26 Shetty R, Seddighzadeh A, Piazza G. et al. Chronic obstructive pulmonary disease and deep vein thrombosis: a prevalent combination. J Thromb Thrombolysis 2008; 26: 35-40.
  CrossrefPubMedGoogle Scholar
• 27 Kelly J, Rudd A, Lewis R. et al. Venous thromboembolism after acute stroke. Stroke 2001; 32: 262-267.
  CrossrefPubMedGoogle Scholar
• 28 Beemath A, Stein PD, Skaf E. et al. Risk of venous thromboembolism in patients hospitalised with heart failure. Am J Cardiol 2006; 98: 793-795.
  CrossrefPubMedGoogle Scholar
• 29 Seddighzadeh A, Shetty R, Goldhaber SZ. Venous thromboembolism in patients with active cancer. Thromb Haemost 2007; 98: 656-661.
  Article in Thieme ConnectPubMedGoogle Scholar
• 30 Piazza G, Seddighzadeh A, Goldhaber SZ. Heart failure in patients with deep vein thrombosis. Am J Cardiol 2008; 101: 1056-1059.
  CrossrefPubMedGoogle Scholar
• 31 Wein L, Wein S, Haas SJ. et al. Pharmacological venous thromboembolism prophylaxis in hospitalised medical patients: a meta-analysis of randomized controlled trials. Arch Intern Med 2007; 167: 1476-1486.
  CrossrefPubMedGoogle Scholar
• 32 Samama MM, Cohen AT, Darmon JY. et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800.
  CrossrefPubMedGoogle Scholar
• 33 Leizorovicz A, Cohen AT, Turpie AG. et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
  CrossrefPubMedGoogle Scholar
• 34 Dentali F, Douketis JD, Gianni M. et al. Metaanalysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalised medical patients. Ann Intern Med 2007; 146: 278-288.
  CrossrefPubMedGoogle Scholar
• 35 Cohen AT, Davidson BL, Gallus AS. et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. Br Med J 2006; 332: 325-329.
  CrossrefPubMedGoogle Scholar
• 36 The surgeon general’s call to action to prevent deep vein thrombosis and pulmonary embolism. U.S. Department of Health and Human Services. 2008 Available at: http://www.surgeongeneral.gov/topics/deepvein/calltoaction/call-to-action-on-dvt-2008.pdf Accessed 11/30/08.
  PubMedGoogle Scholar
• 37 Kucher N, Koo S, Quiroz R. et al. Electronic alerts to prevent venous thromboembolism among hospitalised patients. N Engl J Med 2005; 352: 969-977.
  CrossrefPubMedGoogle Scholar
• 38 Lecumberri R, Marques M, Diaz-Navarlaz MT. et al. Maintained effectiveness of an electronic alert system to prevent venous thromboembolism among hospitalised patients. Thromb Haemost 2008; 100: 699-704.
  Article in Thieme ConnectPubMedGoogle Scholar
• 39 Piazza G, Rosenbaum E, Pendergast W. et al. Physician alerts to prevent symptomatic venous thromboembolism in hospitalised patients. Circulation 2009; 119: 2196-2201.
  CrossrefPubMedGoogle Scholar